Stock RGLS REGULUS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Real-time Estimate Cboe BZX
Other stock markets
 10:25:31 2024-04-19 am EDT 		5-day change 1st Jan Change
2.175 USD -2.03% Intraday chart for Regulus Therapeutics Inc. -20.36% +74.22%
Mar. 21 Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 21 Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Evolution of the average Target Price on Regulus Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

eade60fc8.KCSdalvvdFv2LigQl2xjV7irIFO4pao-thJQQj0PbZk.YmKsXGmALjG8bRFi4V8WFvDfRiSMwP9I4SQjL2pQB89MCfQoNJkAIaZIGA~26648ace0808300811603a4bc2510d01

Analyst Recommendations on Regulus Therapeutics Inc.

Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating MT
Leerink Partners Initiates Regulus Therapeutics at Outperform Rating With $6 Price Target MT
Wells Fargo Adjusts Regulus Therapeutics Price Target to $3 From $2, Maintains Equal Weight Rating MT
Canaccord Genuity Raises Regulus Therapeutics' Price Target to $12 From $9, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Regulus Therapeutics to $9 From $20, Maintains Buy Rating MT
Canaccord Genuity Starts Regulus Therapeutics at Buy With $9 Price Target MT
Wedbush Adjusts Regulus Therapeutics' Price Target to $0.42 From $1 Following Private Equity Placement; Neutral Rating Kept MT
REGULUS THERAPEUTICS : Cantor Fitzgerald Reinstates Regulus Therapeutics at Overweight with $2 Price Target MT
REGULUS THERAPEUTICS : Wedbush Halves Regulus Therapeutics' PT to $1 From $2 on RGLD4326 Timeline for Autosomal Dominant Polycystic Kidney Disease; Neutral Rating Kept MT
REGULUS THERAPEUTICS : HC Wainwright Adjusts Regulus Therapeutics' Price Target to $2 From $1.50, Maintains Buy Rating MT
REGULUS THERAPEUTICS : Wedbush Adjusts Price Target on Regulus Therapeutics to $2 From $1, Maintains Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.22 USD
Average target price
7.25 USD
Spread / Average Target
+226.58%
High Price Target
11 USD
Spread / Highest target
+395.50%
Low Price Target
3 USD
Spread / Lowest Target
+35.14%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Regulus Therapeutics Inc.

Canaccord Genuity
Leerink Partners
Wells Fargo Securities
HC Wainwright
Wedbush
Cantor Fitzgerald

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RGLS Stock
  4. Consensus Regulus Therapeutics Inc.